FDA Making COVID Vax Decision Based on a Study of 10

Pfizer announced preliminary data from Phase 2/3 trials in children 6 months to under 5 years would be submitted to the FDA for emergency use authorization; the data are based on 1,678 children and 10 who got sick, which Pfizer claims is an 80.3% effectiveness rate

Join the World’s #1 Natural Health Newsletter for FREE! Latest Trustworthy News from Dr. Mercola — delivered straight to your inbox!